Anzeige
+++Hot Stock!: China kontrolliert Antimon, eines der hochgradigsten Projekte der Welt?! China kontrolliert Antimon, eines der hochgradigsten Projekte der Welt?!+++
EQS-News

WHO Foundation and Novo Nordisk Expand Collaboration to Provide Financial Support towards strengthening health systems for Cardio-Renal-Metabolic Diseases 11.03.2026, 12:05 Uhr von EQS News Jetzt kommentieren: 0

EQS-News: WHO Foundation / Key word(s): Joint Venture/ESG
WHO Foundation and Novo Nordisk Expand Collaboration to Provide Financial Support towards strengthening health systems for Cardio-Renal-Metabolic Diseases

11.03.2026 / 12:05 CET/CEST
The issuer is solely responsible for the content of this announcement.


GENEVA, March 11, 2026 /PRNewswire/ -- The WHO Foundation today announced an expanded collaboration with Novo Nordisk to support global efforts to strengthen health systems against the rising burden of cardio-renal-metabolic diseases, including obesity and diabetes.

Representatives from the WHO Foundation, Novo Nordisk, and health partners gathered at the launch of the Roadmap for Promoting Health and Addressing Childhood Obesity in School Settings under the Shine India initiative, marking a collaborative step toward preventing childhood obesity and promoting healthier school environments in India.

Novo Nordisk has committed a total of USD 7.9 million to support this effort, with an initial gift of USD 2.9 million in 2024 followed by an additional USD 5 million in December 2025.

The contribution will enable the WHO Foundation to support WHO's broader efforts to address noncommunicable diseases through prevention, early action, and strengthened primary health care, particularly in low- and middle-income countries where health systems often face capacity constraints.

"Cardio-renal-metabolic diseases are complex conditions that demand prevention-first approaches anchored in strong and resilient health systems," said Anil Soni, Chief Executive Officer of the WHO Foundation. "By supporting WHO's leadership on prevention, we can reinforce the science and public health foundations that countries need to respond effectively and equitably."

"Addressing obesity, diabetes and related conditions requires partnership at scale — working across governments, communities, civil society and the private sector to advance prevention, early detection and care. In expanding Novo Nordisk's contribution to the WHO Foundation, we hope that more countries will be empowered with the tools, evidence and resources they need to make impactful local action." Said Elin Jäger, Senior Vice President, Corporate Strategy & Sustainability, Novo Nordisk.

Global context on obesity

  • More than 1 billion people worldwide are living with obesity, including 650 million adults, 340 million adolescents, and 39 million children.
  • Worldwide obesity has nearly tripled since 1975.
  • Overweight and obesity cause more deaths globally than underweight.
  • 39 million children under age 5 are overweight or obese, and more than 340 million people aged 5–19 live with overweight or obesity.

About the WHO Foundation

The WHO Foundation is an independent organization headquartered in Geneva, Switzerland, created in 2020 to support the mission of the World Health Organization. It mobilizes philanthropic capital and builds catalytic partnerships to advance health equity, respond to urgent health challenges, and strengthen systems that save lives. By connecting partners and practitioners, the Foundation helps scale trusted solutions, fund life-saving responses, and drive lasting change toward Health for All. Learn more at who.foundation

 

Photo - https://mma.prnewswire.com/media/2931415/WHO_Foundation.jpg
Logo - https://mma.prnewswire.com/media/2531138/5858327/WHO_Foundation_Logo.jpg

 

WHO Foundation Logo

 

 

Cision View original content:https://www.prnewswire.co.uk/news-releases/who-foundation-and-novo-nordisk-expand-collaboration-to-provide-financial-support-towards-strengthening-health-systems-for-cardio-renal-metabolic-diseases-302710827.html

rt.gif?NewsItemId=EN07686&Transmission_Id=202603110700PR_NEWS_EURO_ND__EN07686&DateId=20260311


11.03.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


2289642  11.03.2026 CET/CEST

Kommentare (0) ... diskutiere mit.
Werbung

Handeln Sie Aktien bei SMARTBROKER+ für 0 Euro!* Profitieren Sie von kostenloser Depotführung, Zugriff auf 29 deutsche und internationale Börsenplätze und unschlagbar günstigen Konditionen – alles in einer innovativen, brandneuen App. Jetzt zu SMARTBROKER+ wechseln und durchstarten!

*Ab 500 EUR Ordervolumen über gettex. Zzgl. marktüblicher Spreads und Zuwendungen.

k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
Weitere News

Gestern 21:10 Uhr • Artikel • dpa-AFX

Gestern 20:47 Uhr • Artikel • dpa-AFX

Gestern 20:35 Uhr • Artikel • dpa-AFX

Gestern 20:33 Uhr • Artikel • dpa-AFX

Gestern 20:19 Uhr • Artikel • dpa-AFX

Gestern 19:21 Uhr • Artikel • dpa-AFX

Schreib den ersten Kommentar!

Dis­clai­mer: Die hier an­ge­bo­te­nen Bei­trä­ge die­nen aus­schließ­lich der In­for­ma­t­ion und stel­len kei­ne Kauf- bzw. Ver­kaufs­em­pfeh­lung­en dar. Sie sind we­der ex­pli­zit noch im­pli­zit als Zu­sich­er­ung ei­ner be­stim­mt­en Kurs­ent­wick­lung der ge­nan­nt­en Fi­nanz­in­stru­men­te oder als Handl­ungs­auf­for­der­ung zu ver­steh­en. Der Er­werb von Wert­pa­pier­en birgt Ri­si­ken, die zum To­tal­ver­lust des ein­ge­setz­ten Ka­pi­tals füh­ren kön­nen. Die In­for­ma­tion­en er­setz­en kei­ne, auf die in­di­vi­du­el­len Be­dür­fnis­se aus­ge­rich­te­te, fach­kun­di­ge An­la­ge­be­ra­tung. Ei­ne Haf­tung oder Ga­ran­tie für die Ak­tu­ali­tät, Rich­tig­keit, An­ge­mes­sen­heit und Vol­lständ­ig­keit der zur Ver­fü­gung ge­stel­lt­en In­for­ma­tion­en so­wie für Ver­mö­gens­schä­den wird we­der aus­drück­lich noch stil­lschwei­gend über­nom­men. Die Mar­kets In­side Me­dia GmbH hat auf die ver­öf­fent­lich­ten In­hal­te kei­ner­lei Ein­fluss und vor Ver­öf­fent­lich­ung der Bei­trä­ge kei­ne Ken­nt­nis über In­halt und Ge­gen­stand die­ser. Die Ver­öf­fent­lich­ung der na­ment­lich ge­kenn­zeich­net­en Bei­trä­ge er­folgt ei­gen­ver­ant­wort­lich durch Au­tor­en wie z.B. Gast­kom­men­ta­tor­en, Nach­richt­en­ag­en­tur­en, Un­ter­neh­men. In­fol­ge­des­sen kön­nen die In­hal­te der Bei­trä­ge auch nicht von An­la­ge­in­te­res­sen der Mar­kets In­side Me­dia GmbH und/oder sei­nen Mit­ar­bei­tern oder Or­ga­nen be­stim­mt sein. Die Gast­kom­men­ta­tor­en, Nach­rich­ten­ag­en­tur­en, Un­ter­neh­men ge­hör­en nicht der Re­dak­tion der Mar­kets In­side Me­dia GmbH an. Ihre Mei­nung­en spie­geln nicht not­wen­di­ger­wei­se die Mei­nung­en und Auf­fas­sung­en der Mar­kets In­side Me­dia GmbH und de­ren Mit­ar­bei­ter wie­der. Aus­führ­lich­er Dis­clai­mer